Skip to content
Screener

PP&E (Net) at other companies

Jazz Pharmaceuticals logo
Jazz PharmaceuticalsJAZZ
$203.1M+13.5%
Xenon Pharmaceuticals logo
Xenon PharmaceuticalsXENE
$7.77M-15.5%
Stoke Therapeutics, Inc. logo
Stoke Therapeutics, Inc.STOK
$3.4M-6.0%
Rapport Therapeutics, Inc. logo
Rapport Therapeutics, Inc.RAPP
$2.34M-26.3%
Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX
$90.9M+4.5%
Biogen logo
BiogenBIIB
$2.99B-3.4%

Other financials

Income statement

See full
Revenue--100%
Operating income-$96.9M-27.4%
Net income-$83.7M-17.7%
EPS (diluted)-$2.87+13.3%

Balance sheet

See full
Cash & equivalents$474.8M+201%
Total debt$1.1M+44.0%
Total equity$1.3B+232%
Total assets$1.4B+207%

Cash flow

See full
Operating cash flow-$77.5M-41.8%
CapEx$245.0K+338%
Free cash flow-$77.8M-42.1%

Valuation

See full
Market cap$8.9B+770%
Enterprise value$8.43B+873%

Profitability

See full
Operating margin-3,927.5%-1,497pp
Net margin-3,658.5%-1,388pp
FCF margin-3,067.4%-1,030pp

Returns & leverage

See full
Return on equity-38.9%-10.3pp
Debt / equity0.0×
Current ratio15.7×+9.4×

Where this comes from

Reported directly by Praxis Precision Medicines, Inc. in its filing.

Tagged under the XBRL concept us-gaap:PropertyPlantAndEquipmentNet.

The source filing: Praxis Precision Medicines, Inc.’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 8:32 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001689548-26-000083
Line itemJune 30, 2026December 31, 2025
Prepaid expenses and other current assets13,35211,580
Total current assets771,903610,911
Long-term marketable securities615,290326,757
Property and equipment, net492147
Operating lease right-of-use assets1,00192
Internal-use software773
Other assets643
Total assets$1,390,102$937,907

Item 1. Financial Statements (Unaudited)

FAQ

What is Praxis Precision Medicines, Inc.'s PP&E (net)?
Praxis Precision Medicines, Inc. (PRAX) reported PP&E (net) of $492K in Q2 2026.
How has Praxis Precision Medicines, Inc.'s PP&E (net) changed year-over-year?
Praxis Precision Medicines, Inc.'s PP&E (net) increased by 90.7% year-over-year, from $258K to $492K.
What is the long-term trend for Praxis Precision Medicines, Inc.'s PP&E (net)?
Over 5 years (2020 to 2025), Praxis Precision Medicines, Inc.'s PP&E (net) has grown at a 12.4% compound annual growth rate (CAGR), from $82K to $147K.
What does PP&E (net) mean?
Total property, plant, and equipment minus accumulated depreciation — the net book value of all tangible long-lived assets.

Ask your AI about Praxis Precision Medicines, Inc.'s pp&e (net).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude